We are live on ! Find out more
FOMX

Foamix Pharmaceuticals
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

56 hedge funds and large institutions have $102M invested in Foamix Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 13

2.91% less ownership

Funds ownership: 61.46% → 58.55% (-2.9%)

16% less funds holding

Funds holding: 67 → 56 (-11)

29% less capital inflows, than outflows

Capital inflows: $13.6M | Capital outflows: $19.3M

56% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 18

96% less call options, than puts

Call options by funds: $9K | Put options by funds: $206K

Holders
56
Holders Change
-11
Holders Change %
-16.42%
% of All Funds
1.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
20
Reduced
13
Closed
18
Calls
$9​K
Puts
$206​K
Net Calls
-⁠$197​K
Net Calls Change
-⁠$3.62​M

FOMX Hedge Fund Activity: Q2 2017 in Review

56 of the 4,025 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals (FOMX) for Q2 2017, worth a combined $102M — down 10% from $113M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of FOMX and 8 opened new positions — a net loss of 10 holders — while 13 trimmed existing stakes and 20 added.

The largest buyer was Great Point Partners, adding an estimated $4.91M. The largest seller was RA Capital Management, exiting entirely with an estimated $9.01M sold.

  • 56 institutional investors held Foamix Pharmaceuticals (FOMX) as of Q2 2017, down from 67 in Q1 2017.
  • Funds reported $102M of Foamix Pharmaceuticals stock for Q2 2017, down 10% quarter-over-quarter.
  • 8 funds opened new Foamix Pharmaceuticals positions in Q2 2017 and 18 closed out, a net change of -10 holders.
  • The largest Foamix Pharmaceuticals buyer in Q2 2017 was Great Point Partners, an estimated $4.91M added.
  • The largest Foamix Pharmaceuticals seller in Q2 2017 was RA Capital Management, an estimated $9.01M sold.

Based on aggregated 13F filings for Q2 2017.